Methods: Fifteen patients with confirmed HER2-positive breast cancer underwent simultaneous PET/MRI 5–7 d after receiving 77 ± 1.9 MBq of [89Zr]Zr-trastuzumab. Here, ERBB2 is linked to breast cancer.